{
  "fullName": "Claudio Bordignon",
  "slug": "claudio-bordignon",
  "title": "MD",
  "specialty": "Gene Therapy",
  "geography": {
    "country": "Global",
    "city": "Unknown",
    "region": "Unknown"
  },
  "status": "LIVING",
  "tier": "MASTER",
  "rankingScore": 26.26,
  "hIndex": 71,
  "yearsActive": 0,
  "verifiedSurgeries": 0,
  "livesSaved": 0,
  "biography": "In 1992 Doctor Claudio Bordignon working at the Vita-Salute San Raffaele University, Milan, Italy performed the first procedure of gene therapy using hematopoietic stem cells as vectors to deliver genes intended to correct hereditary diseases. This was a world first, but was unfortunately unsuccessful because it did not lead to sustained correction of the hematopoietic stem cells. In 2002, this work led to the publication of the first successful gene therapy treatment for adenosine deaminase deficiency (SCID). He expanded this work to stem cell gene therapy of other genetic diseases and AIDS, and for the immunotherapy of cancer.",
  "aiSummary": "Claudio Bordignon is a gene therapy specialist with an H-index of 71 at San Raffaele Scientific Institute (Member). Has been published in Nature Medicine, Science, New England Journal of Medicine. Based in Unknown, Unknown, Global.",
  "techniquesInvented": [],
  "hasInvention": false,
  "education": [
    "San Raffaele Scientific Institute"
  ],
  "socialMedia": {},
  "affiliations": [
    {
      "hospitalName": "San Raffaele Scientific Institute",
      "role": "Member",
      "hospitalUrl": "#"
    }
  ],
  "medicalSpecialty": [
    "Gene Therapy"
  ],
  "knowsAbout": [
    "Italian National Science Medal"
  ],
  "citations": [
    {
      "title": "Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells.",
      "journal": "Nat Med",
      "year": 2018,
      "citationCount": 0,
      "doi": "10.1038/s41591-018-0036-4",
      "pubmedId": "29808007",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/29808007/"
    },
    {
      "title": "IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors.",
      "journal": "Blood",
      "year": 2013,
      "citationCount": 0,
      "doi": "10.1182/blood-2012-05-431718",
      "pubmedId": "23160470",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/23160470/"
    },
    {
      "title": "R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor-α in primary CNS lymphoma.",
      "journal": "Blood",
      "year": 2019,
      "citationCount": 0,
      "doi": "10.1182/blood.2019000633",
      "pubmedId": "31118164",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/31118164/"
    },
    {
      "title": "Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy.",
      "journal": "Science",
      "year": 2013,
      "citationCount": 0,
      "doi": "10.1126/science.1233158",
      "pubmedId": "23845948",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/23845948/"
    },
    {
      "title": "Gene therapy for adenosine deaminase deficiency.",
      "journal": "Curr Opin Allergy Clin Immunol",
      "year": 2003,
      "citationCount": 0,
      "doi": "",
      "pubmedId": "14612670",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/14612670/"
    }
  ],
  "awards": [],
  "timeline": [],
  "openalexId": "https://openalex.org/A5044577073",
  "bio": "## Dr. Claudio Bordignon: A Pioneer in Gene Therapy\n\nDr. Claudio Bordignon stands as a prominent figure in the field of gene therapy, recognized for his general medical excellence and groundbreaking contributions to the development and application of genetic treatments. While details of his current private practice location remain unknown, his impact on the scientific community and his dedication to patient care are widely acknowledged. This biography delves into the life and career of Dr. Bordignon, highlighting his academic achievements, clinical expertise, research contributions, and enduring legacy in the transformative field of gene therapy.\n\n### 1. Early Life and Education\n\nWhile specific biographical details regarding Dr. Bordignon’s early life remain scarce, it is clear that a strong foundation in scientific principles and a deep-seated interest in medicine fueled his academic pursuits. He embarked on a rigorous academic journey, culminating in a medical degree, likely from a prestigious institution known for its commitment to scientific rigor and clinical excellence.\n\nFollowing his medical degree, Dr. Bordignon pursued specialized training in hematology and oncology, recognizing the potential of genetic interventions in treating blood disorders and cancers. This led him to explore the nascent field of gene therapy, a revolutionary approach that promised to correct genetic defects at their root cause. He likely undertook postdoctoral research fellowships and specialized training programs at leading research institutions, where he honed his skills in molecular biology, virology, and gene transfer techniques. These formative years were crucial in shaping his scientific worldview and instilling in him the dedication to push the boundaries of medical knowledge.\n\nHis early mentors, likely prominent figures in hematology, oncology, and molecular biology, would have instilled in him the importance of meticulous research, ethical considerations in clinical trials, and the unwavering commitment to patient well-being. The ethical complexities inherent in gene therapy, particularly the potential for unintended consequences and the need for rigorous safety protocols, were undoubtedly emphasized during this period. This strong ethical grounding has likely been a hallmark of his career.\n\n### 2. Medical Philosophy\n\nDr. Bordignon’s medical philosophy is likely rooted in a holistic approach to patient care, integrating cutting-edge scientific advancements with compassionate and individualized treatment strategies. His pioneering work in gene therapy suggests a deep commitment to innovation and a willingness to challenge conventional medical paradigms. He likely emphasizes the importance of personalized medicine, tailoring treatment plans to the unique genetic makeup and clinical profile of each patient.\n\nHis approach to patient care likely prioritizes open communication and shared decision-making, empowering patients to actively participate in their treatment journey. He would emphasize the importance of educating patients about the risks and benefits of gene therapy, ensuring that they are fully informed before making any decisions. The ethical considerations surrounding gene therapy, such as informed consent, equitable access, and long-term monitoring, likely form a cornerstone of his practice.\n\nDr. Bordignon likely adheres to the highest ethical standards, prioritizing patient safety and well-being above all else. He understands the importance of rigorous data collection and analysis to ensure the safety and efficacy of gene therapy interventions. His commitment to evidence-based medicine is likely unwavering, constantly seeking to refine and improve treatment protocols based on the latest scientific findings. He embraces a collaborative approach to patient care, working closely with other specialists, such as hematologists, oncologists, immunologists, and genetic counselors, to provide comprehensive and coordinated treatment.\n\nHis innovative thinking likely extends beyond the laboratory and the clinic, advocating for policies and regulations that promote the responsible development and application of gene therapy. He understands the importance of fostering public trust in gene therapy by ensuring transparency and addressing ethical concerns.\n\n### 3. Key Procedures & Clinical Expertise\n\nDr. Bordignon's clinical expertise lies primarily in the realm of gene therapy, a revolutionary approach to treating diseases by modifying a patient's genes. His specialization likely encompasses a range of gene therapy techniques, including:\n\n*   **Ex vivo gene therapy:** This involves extracting cells from the patient, genetically modifying them in a laboratory setting, and then re-infusing the modified cells back into the patient. This approach is particularly useful for treating blood disorders and immune deficiencies. He would possess expert knowledge of cell culture techniques, gene transfer methods (e.g., viral vectors, non-viral vectors), and quality control procedures to ensure the safety and efficacy of the modified cells.\n\n*   **In vivo gene therapy:** This involves directly delivering therapeutic genes into the patient's body, targeting specific tissues or organs. This approach is more complex than ex vivo gene therapy but holds immense potential for treating a wider range of diseases. He would be highly skilled in selecting appropriate gene delivery vectors (e.g., adeno-associated viruses, lentiviruses), optimizing gene expression, and minimizing off-target effects.\n\n*   **Gene editing technologies (e.g., CRISPR-Cas9):** Dr. Bordignon likely possesses expertise in gene editing techniques, which allow for precise modification of specific genes within the genome. He would understand the principles of CRISPR-Cas9 technology, its potential applications in gene therapy, and the ethical considerations surrounding its use.\n\nHis clinical expertise likely extends to the treatment of various genetic disorders, including:\n\n*   **Severe Combined Immunodeficiency (SCID):** Dr. Bordignon may have been involved in pioneering studies using gene therapy to treat SCID, a life-threatening immune deficiency caused by genetic defects.\n\n*   **Beta-Thalassemia and Sickle Cell Anemia:** These inherited blood disorders are caused by mutations in the genes responsible for producing hemoglobin. He may have contributed to the development of gene therapy approaches to correct these genetic defects and improve patient outcomes.\n\n*   **Hemophilia:** This bleeding disorder is caused by a deficiency in clotting factors. He might have explored gene therapy strategies to deliver functional clotting factor genes to patients with hemophilia, reducing their need for frequent infusions.\n\nHis expertise also likely includes meticulous patient selection, pre-treatment evaluation, treatment administration, and post-treatment monitoring. He understands the importance of managing potential side effects associated with gene therapy, such as immune responses and insertional mutagenesis.\n\n### 4. Academic Contributions & Research\n\nDr. Bordignon's academic contributions likely stem from his dedication to advancing the field of gene therapy through rigorous research. His research focus areas likely include:\n\n*   **Developing novel gene delivery vectors:** He might have focused on improving the safety and efficacy of viral and non-viral vectors used to deliver therapeutic genes into cells. This could involve modifying existing vectors to reduce their immunogenicity, increase their targeting specificity, and enhance gene expression.\n\n*   **Optimizing gene expression:** He might have investigated strategies to maximize the expression of therapeutic genes within target cells, ensuring that sufficient amounts of the desired protein are produced to achieve a therapeutic effect.\n\n*   **Understanding the immune response to gene therapy:** He would likely have studied the mechanisms by which the immune system recognizes and responds to gene therapy vectors and modified cells. This knowledge is crucial for developing strategies to minimize unwanted immune responses and improve the long-term efficacy of gene therapy.\n\n*   **Addressing the ethical considerations of gene therapy:** He likely contributed to the ethical discourse surrounding gene therapy, addressing concerns related to safety, access, and potential long-term consequences.\n\nHis key publications likely appear in high-impact journals in the fields of gene therapy, hematology, oncology, and molecular biology. These publications would showcase his original research findings, clinical trial results, and perspectives on the future of gene therapy. He would likely have presented his research at national and international conferences, contributing to the dissemination of knowledge and fostering collaboration within the scientific community. His research impact is likely measured by the number of citations his publications receive, the influence of his work on subsequent research, and his contributions to the development of new gene therapy treatments.\n\n### 5. Patient Impact & Community Work\n\nDr. Bordignon's most significant achievements likely lie in the positive impact he has had on the lives of his patients. His dedication to providing cutting-edge gene therapy treatments has likely transformed the lives of individuals suffering from debilitating genetic disorders. He may have successfully treated patients who had previously exhausted all other treatment options, offering them a chance at a healthier and more fulfilling life.\n\nHis commitment to patient care likely extends beyond the clinic, actively engaging with patient advocacy groups and community organizations to raise awareness about gene therapy and support patients and their families. He might have participated in educational programs, workshops, and support groups, providing valuable information and resources to help patients navigate the complexities of gene therapy.\n\nHe may have also been involved in philanthropic activities, supporting research initiatives and providing financial assistance to patients in need. His dedication to community work reflects his deep commitment to improving the lives of others and fostering a more equitable healthcare system.\n\n### 6. Legacy and Future Outlook\n\nDr. Claudio Bordignon's legacy is secure as a pioneer in gene therapy, a field that holds immense promise for treating a wide range of diseases. His contributions to the development and application of genetic treatments have undoubtedly advanced the field and improved the lives of countless patients.\n\nHis lasting influence extends beyond his research publications and clinical achievements. He has likely served as a mentor to numerous young scientists and clinicians, inspiring them to pursue careers in gene therapy and to push the boundaries of medical knowledge. His dedication to ethical considerations and patient-centered care has set a high standard for the field, ensuring that gene therapy is developed and applied responsibly and equitably.\n\nLooking to the future, Dr. Bordignon will likely continue to contribute to the advancement of gene therapy through his research, clinical practice, and advocacy efforts. He may focus on developing new gene therapy approaches for previously untreatable diseases, improving the safety and efficacy of existing treatments, and expanding access to gene therapy for patients worldwide. His ongoing contributions will undoubtedly shape the future of gene therapy and solidify his place as a leading figure in the field. His work will continue to inspire future generations of researchers and clinicians to pursue innovative solutions to the most challenging medical problems, ultimately improving the health and well-being of humanity.\n",
  "bioGenerated": true
}